Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,385 | 331 | 2,001 |
| Samples | 462 | 95 | 353 |
| Peptides | 415 | 85 | 327 |
Function
MYO1C · Myosin IC
This gene encodes a member of the unconventional myosin protein family, which are actin-based molecular motors. The protein is found in the cytoplasm, and one isoform with a unique N-terminus is also found in the nucleus. The nuclear isoform associates with RNA polymerase I and II and functions in transcription initiation. The mouse ortholog of this protein also functions in intracellular vesicle transport to the plasma membrane. Multiple transcript variants encoding different isoforms have been found for this gene. The related gene myosin IE has been referred to as myosin IC in the literature, but it is a distinct locus on chromosome 19. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
8 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 325 amino-acid changes on canonical ENST00000361007 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MYO1C · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MYO1C – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Chordoma | 1/7 14% | 0/13 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Endometrial Carcinoma | 7/42 17% | 18/612 3% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Colorectal Carcinoma | 18/143 13% | 74/3239 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Melanoma | 4/210 2% | 34/1899 2% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 19/1390 1% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Gastric Carcinoma | 1/74 1% | 27/1809 1% |
| Bladder Carcinoma | 2/58 3% | 11/956 1% |
| Other Sarcomas | 0/69 0% | 9/699 1% |
| Other Solid Cancers | 4/94 4% | 14/1515 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Head and Neck Carcinoma | 2/85 2% | 16/1574 1% |
| Esophageal Squamous Cell Carcinoma | 5/51 10% | 22/2550 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Plasma Cell Myeloma | 0/44 0% | 3/305 1% |
| Neuroendocrine Tumour | 4/154 3% | 2/577 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 5/810 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Hepatocellular Carcinoma | 2/46 4% | 13/2210 1% |
| Non-Cancerous | 1/104 1% | 5/830 1% |
| Glioma | 4/52 8% | 10/2127 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
Mutation Distribution
Where MYO1C is mutated · all tissues, split by cell line vs tissue
How many mutations in MYO1C were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,385 mutations in MYO1C
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|